본문 바로가기
KERD
논문KCI 등재

Duchenne 근디스트로피의 치료에 대한 고찰

Treatment of Duchenne Muscular Dystrophy: A Comprehensive Review

최영철|박형준
대한신경과학회 (Korean Neurological Association)|2012.11|대한신경과학회지 (Journal of the Korean Neurological Association)|제30권 제4호|pp. 257-266

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

CorticosteroidsGene therapyDuchenne muscular dystrophyCell therapy
주제분류신경과학

초록

Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder due to the loss of dystrophin in muscle fiber. The deficiency of dystrophin produces severe progressive muscle degeneration which leads to progressive muscle weakness. Affected patients usually become unambulatory in their early teens, and suffer a respiratory failure before 20 years of age. In an attempt to improve quality of life and extend life span of DMD patients, various treatments have been challenged; corticosteroid trial, rehabilitation, cardiac and pulmonary managements, orthopedic interventions, and nutritional support. However, only corticosteroid therapy and non-invasive ventilation have shown a salutary effect on the clinical course of DMD. Recently, a better understanding of the DMD pathophysiology has provided the scientific basis for new treatment modalities including cell and molecular therapy. Although previous clinical trials have demonstrated the limitation and possibility of new therapies, antisense-mediated exon skipping technology is now emerging as a promising approach to restore dystrophin expression. This article summarizes the current challenges and recommendations of treatment approaches in DMD patients.

Abstract

Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder due to the loss of dystrophin in muscle fiber. The deficiency of dystrophin produces severe progressive muscle degeneration which leads to progressive muscle weakness. Affected patients usually become unambulatory in their early teens, and suffer a respiratory failure before 20 years of age. In an attempt to improve quality of life and extend life span of DMD patients, various treatments have been challenged; corticosteroid trial, rehabilitation, cardiac and pulmonary managements, orthopedic interventions, and nutritional support. However, only corticosteroid therapy and non-invasive ventilation have shown a salutary effect on the clinical course of DMD. Recently, a better understanding of the DMD pathophysiology has provided the scientific basis for new treatment modalities including cell and molecular therapy. Although previous clinical trials have demonstrated the limitation and possibility of new therapies, antisense-mediated exon skipping technology is now emerging as a promising approach to restore dystrophin expression. This article summarizes the current challenges and recommendations of treatment approaches in DMD patients.

참고문헌 (71)

  1. Sinnreich M., "Disorders of voluntary muscle", pp.205~229 (2009), Cambridge University Press
  2. Emery AE., "Population frequencies of inherited neuromuscular diseases--a world survey", Neuromuscul Disord, 1, pp.19~29 (1991)
  3. Koenig M, "Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals", Cell, 50, pp.509~517 (1987)
  4. Eagle M., "Report on the muscular dystrophy campaign workshop: exercise in neuromuscular diseases Newcastle, January 2002", Neuromuscul Disord, 12, pp.975~983 (2002)
  5. Sussman M., "Duchenne muscular dystrophy", J Am Acad Orthop Surg, 10, pp.138~151 (2002)
  6. Velasco MV, "Posterior spinal fusion for scoliosis in duchenne muscular dystrophy diminishes the rate of respiratory decline", Spine, 32, pp.459~465 (2007)
  7. Heller KD, "Spinal stabilization in Duchenne muscular dystrophy: principles of treatment and record of 31 operative treated cases", J Pediatr Orthop B, 10, pp.18~24 (2001)
  8. Ciafaloni E, "Treatment options for Duchenne muscular dystrophy", Curr Treat Options Neurol, 10, pp.86~93 (2008)
  9. American Academy of Pediatrics Section on Cardiology and Cardiac Surgery, "Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy", Pediatrics, 116, pp.1569~1573 (2005)
  10. Eagle M, "Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation", Neuromuscul Disord, 12, pp.926~929 (2002)
  11. Bushby K, "107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy", Neuromuscular Disord, 13, pp.166~172 (2003)
  12. Hyde SA, "A randomized comparative study of two methods for controlling Tendo Achilles contracture in Duchenne muscular dystrophy", Neuromuscul Disord, 10 (2000)
  13. McDonald CM, "Limb contractures in progressive neuromuscular disease and the role of stretching, orthotics, and surgery", Phys Med Rehabil Clin N Am, 9, pp.187~211 (1998)
  14. Bakker JP, "The effects of knee-ankle-foot orthoses in the treatment of Duchenne muscular dystrophy: review of the literature", Clin Rehabil, 14, pp.343~359 (2000)
  15. Moxley RT 3rd, "Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society", Neurology, 64, pp.13~20 (2005)
  16. Angelini C, "The role of corticosteroids in muscular dystrophy: a critical appraisal", Muscle Nerve, 36, pp.424~435 (2007)
  17. Biggar WD, "Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade", Neuromuscul Disord, 16, pp.249~255 (2006)
  18. Houde S, "Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up", Pediatr Neurol, 38, pp.200~206 (2008)
  19. Markham LW, "Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy", Neuromuscul Disord, 18, pp.365~370 (2008)
  20. Florence JM, "Clinical trials in Duchenne dystrophy. Standardization and reliability of evaluation procedures", Phys Ther, 64, pp.41~45 (1984)
  21. Brooke MH, "Clinical trial in Duchenne dystrophy", Muscle Nerve, 4, pp.186~197 (1981)
  22. Griggs RC, "Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group", Arch Neurol, 48, pp.383~388 (1991)
  23. Mesa LE, "Steroids in Duchenne muscular dystrophy--deflazacort trial", Neuromuscul Disord, 1, pp.261~266 (1991)
  24. Biggar WD, "Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols", Neuromuscul Disord, 14, pp.476~482 (2004)
  25. Mendell JR, "Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy", N Engl J Med, 320, pp.1592~1597 (1989)
  26. Bushby K, "Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management", Lancet Neurol, 9, pp.77~93 (2010)
  27. Escolar DM, "CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy", Ann Neurol, 58(1), pp.151~155 (2005)
  28. Renault V, "Regenerative potential of human skeletal muscle during aging", Aging Cell, 1, pp.132~139 (2002)
  29. Heslop L, "Evidence for a myogenic stem cell that is exhausted in dystrophic muscle", J Cell Sci, 113(12), pp.2299~2308 (2000)
  30. Huard J, "High efficiency of muscle regeneration after human myoblast clone transplantation in SCID mice", J Clin Invest, 93, pp.586~599 (1994)
  31. Gussoni E, "Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation", Nature, 356, pp.435~438 (1992)
  32. Mendell JR, "Myoblast transfer in the treatment of Duchenne's muscular dystrophy", N Engl J Med, 333, pp.832~838 (1995)
  33. Beauchamp JR, "Dynamics of myoblast transplantation reveal a discrete minority of precursors with stem cell-like properties as the myogenic source", J Cell Biol, 144, pp.1113~1122 (1999)
  34. Moens PD, "Lack of myoblasts migration between transplanted and host muscles of mdx and normal mice", J Muscle Res Cell Motil, 17, pp.37~43 (1996)
  35. Dellavalle A, "Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells", Nat Cell Biol, 9, pp.255~267 (2007)
  36. Sampaolesi M, "Mesoangioblast stem cells ameliorate musclefunction in dystrophic dogs", Nature, 444, pp.574~579 (2006)
  37. Benchaouir R, "Restoration of human dystrophin followingtransplantation of exon-skipping-engineered DMD patient stem cellsinto dystrophic mice", Cell Stem Cell, 1, pp.646~657 (2007)
  38. Gussoni E, "Long-term persistence of donor nuclei in a Duchennemuscular dystrophy patient receiving bone marrow transplantation", JClin Invest, 110, pp.807~814 (2002)
  39. Dezawa M, "Bone marrow stromal cells generate muscle cells and repair muscle degeneration", Science, 309, pp.314~317 (2005)
  40. Dell'Agnola C, "Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs", Blood, 104, pp.4311~4318 (2004)
  41. Meng J, "The contribution of human synovial stem cells to skeletal muscle regeneration", Neuromuscul Disord, 20, pp.6~15 (2010)
  42. Ichim TE, "Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy", Cell Immunol, 260, pp.75~82 (2010)
  43. Darabi R, "Engraftment of embryonic stem cell-derived myogenic progenitors in a dominant model of muscular dystrophy", Exp Neurol, 220, pp.212~216 (2009)
  44. Mizuno Y, "Generation of skeletal muscle stem", progenitor cells from murine induced pluripotent stem cells, 2010, pp.24, 2245~2253
  45. Wang B, "A canine minidystrophin is functional and therapeutic in mdx mice", Gene Ther, 15, pp.1099~1106 (2008)
  46. Mendell JR, "Dystrophin immunity in Duchenne's muscular dystrophy", N Engl J Med, 363, pp.1429~1437 (2010)
  47. Bachrach E, "Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells", Proc Natl Acad Sci U S A, 101, pp.3581~3586 (2004)
  48. Romero NB, "Phase I study of dystrophin plasmid-based gene therapy in Duchenne", Becker muscular dystrophy, 2004, pp.15, 1065~1076
  49. Wolff J, "Non-viral approaches for gene transfer", Acta Myol, 24, pp.202~208 (2005)
  50. Mir LM, "High-efficiency gene transfer into skeletal muscle mediated by electric pulses", Proc Natl Acad Sci U S A, 96, pp.4262~4267 (1999)
  51. Gissel H, "Excitation-induced Ca2+ influx and skeletal muscle cell damage", Acta Physiol Scand, 171, pp.327~334 (2001)
  52. Chapdelaine P, "Functional EGFP-dystrophin fusion proteins for gene therapy vector development", Protein Eng, 13, pp.611~615 (2000)
  53. Pichavant C, "Electrotransfer of the full-length dog dystrophin into mouse and dystrophic dog muscles", Hum Gene Ther, 21, pp.1591~1601 (2010)
  54. Manuvakhova M, "Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system", RNA, 6, pp.1044~1055 (2000)
  55. Barton-Davis ER, "Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice", J Clin Invest, 104, pp.375~381 (1999)
  56. Wagner KR, "Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations", Ann Neurol, 49, pp.706~711 (2001)
  57. Dunant P, "Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle", MuscleNerve, 27, pp.624~627 (2003)
  58. Pichavant C, "Current status of pharmaceutical and genetic therapeutic approaches to treat DMD", Mol Ther, 19, pp.830~840 (2011)
  59. Dias N, "Antisense oligonucleotides: basic concepts and mechanisms", Mol Cancer Ther, 1, pp.347~355 (2002)
  60. van Deutekom JC, "Local dystrophin restoration with antisense oligonucleotide PRO051", N Engl J Med, 357, pp.2677~2686 (2007)
  61. Adams AM, "Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries", BMC Mol Biol, 8, pp.57~ (2007)
  62. Karpati G, "Utrophin muscles in on the action", Nat Med, 3, pp.22~23 (1997)
  63. Mizuno Y, "Reciprocal expression of dystrophin and utrophin in muscles of Duchenne muscular dystrophy patients, female DMD-carriers and control subjects", J Neurol Sci, 119, pp.43~52 (1993)
  64. Tinsley J, "Expression of full-length utrophin prevents muscular dystrophy in mdx mice", Nat Med, 4, pp.1441~1444 (1998)
  65. Miura P, "Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?", Trends Mol Med, 12, pp.122~129 (2006)
  66. Li D, "Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin", J Cell Sci, 123, pp.2008~2013 (2010)
  67. Bogdanovich S, "Myostatin propeptide-mediated amelioration of dystrophic pathophysiology", FASEB J, 19, pp.543~549 (2005)
  68. Wagner KR, "Loss of myostatin attenuates severity of muscular dystrophy in mdx mice", Ann Neurol, 52, pp.832~836 (2002)
  69. Wagner KR, "A phase I", IItrial of MYO-029 in adult subjects with muscular dystrophy, 2008, pp.63, 561~571
  70. Lee SJ, "Speed and endurance: you can have it all", J Appl Physiol, 109, pp.621~622 (2010)
  71. Bushby K, "Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care", Lancet Neurol, 9, pp.177~189 (2010)

관련 논문AI추천

뒤시엔느형 근디스트로피에서 장기간의 주기적 스테로이드 치료 1예김선미, 김형빈, 박은숙, 장원혁, 장재훈대한근전도전기진단의학회 · 대한근전도 전기진단의학회지2009 · 제11권 제2호유전성 근육질환의 유전자 치료신진홍대한임상신경생리학회 · Annals of Clinical Neurophysiology2012 · 제14권 제2호Cardiac and Pulmonary Management Status of Duchenne Muscular Dystrophy in South Korea Based on Data From the National Health Insurance Database김진미, 박호은, 손정민, 신용범, 윤진아대한신경과학회 · Journal of Clinical Neurology2022 · 제18권 제5호두시엔느 근디스트로피 환자에서 비침습적 환기보조 중 발생한 기흉 − 증례 보고 −강성웅, 백종훈, 이순규, 최원아대한재활의학회 · Annals of Rehabilitation Medicine2009 · 제33권 제6호Correlation of Serum Creatine Kinase Level With Pulmonary Function in Duchenne Muscular Dystrophy강성웅, 김은영, 서미리, 오현준, 이장우, 최원아대한재활의학회 · Annals of Rehabilitation Medicine2017 · 제41권 제2호뒤시엔느 근디스트로피 환자의 영양 상태 평가박윤길, 윤여훈, 정강재, 정철오, 최정화대한근전도전기진단의학회 · 대한근전도 전기진단의학회지2011 · 제13권 제2호

이 간행물의 다른 논문 (32건)

뇌미세혈관병증 3가지 표식과 열공뇌경색 초기 신경학적 악화와의 관련성양미화, 한문구, 장명숙, 배희준, 문장섭, 김나영, 강지훈pp. 267-273한국인 뇌졸중 예측모형에 의한 뇌졸중 10년 발생 위험도와 경동맥 내중막 두께의 관련성양진훈, 이화평, 정보우, 손효경, 이채용pp. 274-278발작과 실신에서 일시적 혈중 암모니아 상승의 차이김지화, 고원, 김혜인, 김원주, 최윤호pp. 279-283플라보노이드 luteolin이 세포자멸사 관련 단백질 활성 억제를 통해 6-hydroxydopamine 세포독성에 미치는 억제효과이선화, 이정수, 강진호, 한정호, 김두응pp. 284-292폐쇄수면무호흡증환자에서 자동 비강기도양압기 사용 후 지속되는 주간졸림의 예측인자구대림, 주은연, 최수정, 홍승봉pp. 293-300
원문 보기